Limited Effectiveness of IL ‐17 Inhibitors for Anti‐ TNF ‐Induced Psoriasis in Hidradenitis Suppurativa: A Multicenter Retrospective Study
International Journal of Dermatology · 2026-12 · 65 (12) · 2515-2523
DOI: 10.1111/ijd.70420 ↗Abstract
ABSTRACT Background Paradoxical psoriasis (PP) is a known adverse event of anti‐tumor necrosis factor (anti‐TNF) agents in hidradenitis suppurativa (HS), yet evidence regarding its management remains limited. The objective was to assess the effectiveness of interleukin‐17 inhibitors (IL‐17i) in treating anti‐TNF‐induced PP in patients with HS. Methods This multicenter retrospective study included 40 adults with HS who developed PP during anti‐TNF therapy and were subsequently treated with IL‐17i. Outcomes for PP were measured using the Physician's Global Assessment (PGA); HS severity was evaluated using the International Hidradenitis Suppurativa Severity Score System (IHS4) and Hurley scores. Paired comparisons were performed using the Wilcoxon signed‐rank or McNemar's test, as appropriate. Multivariate analysis was performed using LASSO‐regularized logistic regression. Missing data were managed by multiple imputation. Results Of the patients, 27.5% achieved a clinically meaningful PP response, while 45% experienced worsening. Female sex, older age at HS onset, and prior exposure to secukinumab were associated with nonresponse. Conversely, HS severity improved significantly in 70% of patients ( p < 0.001). Conclusions IL‐17i showed limited effectiveness for anti‐TNF‐induced PP in HS, though improvement in hidradenitis was observed. image
EUVIMED